The Advanced Therapies Medicinal Product (ATMP) market is growing at an annual growth rate of 15% and has an expected value of
NextCell's subsidiary QVance, based in Huddinge, has been developed to address the specific needs of advanced therapy companies, especially those wanting a locally situated provider of quality analytics. Addressing a gap in the service provision for advanced therapy companies in the Nordics, QVance's business model is based on fee-for-service and vision is to provide local analytics to those in the Nordics, offering an array of quality control assays, product release and bespoke assay development for companies of all sizes. Analytical equipment, cleanroom space and expert staff will be transferred from NextCell to the new company, which will be a service provider for NextCell and other ATMP companies.
"We are leading the development of cell therapies and have identified a growing need for quality analyses in the Nordics. QVance has been borne out of an understanding of what ATMP developers need and what is currently missing in our region. NextCell's own experience has highlighted this gap as we ourselves move through the development pathway of our own drug candidate,
1) Future Markets Insights REP-GB-162421
2) ATMP - ATMP2030 (atmpsweden.se)
For more information about
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva
Certified Adviser
About
NNextCell is a cell therapy company that is in phase 2 studies with the drug candidate
https://news.cision.com/nextcell-pharma-ab/r/nextcell-establishes-qvance-to-meet-the-nordic-s-need-for-quality-analytics,c3945290
https://mb.cision.com/Main/15834/3945290/2667681.pdf
(c) 2024 Cision. All rights reserved., source